<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:38:52Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9006286" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9006286</identifier>
        <datestamp>2022-04-13</datestamp>
        <setSpec>bloodadv</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood Adv</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id>
              <journal-id journal-id-type="hwp">bloodoa</journal-id>
              <journal-id journal-id-type="publisher-id">Blood Advances</journal-id>
              <journal-title-group>
                <journal-title>Blood Advances</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2473-9529</issn>
              <issn pub-type="epub">2473-9537</issn>
              <publisher>
                <publisher-name>American Society of Hematology</publisher-name>
                <publisher-loc>Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9006286</article-id>
              <article-id pub-id-type="pmcid">PMC9006286</article-id>
              <article-id pub-id-type="pmc-uid">9006286</article-id>
              <article-id pub-id-type="pmid">34507355</article-id>
              <article-id pub-id-type="pmid">34507355</article-id>
              <article-id pub-id-type="publisher-id">2022/ADV2021004856</article-id>
              <article-id pub-id-type="doi">10.1182/bloodadvances.2021004856</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>20</subject>
                  <subject>25</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Myeloid Neoplasia</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Genomic profiling of a randomized trial of interferon-Î± vs hydroxyurea in MPN reveals mutation-specific responses</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9829-3099</contrib-id>
                  <name>
                    <surname>Knudsen</surname>
                    <given-names>Trine Alma</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0097-7826</contrib-id>
                  <name>
                    <surname>Skov</surname>
                    <given-names>Vibe</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stevenson</surname>
                    <given-names>Kristen</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Werner</surname>
                    <given-names>Lillian</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Duke</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Laurore</surname>
                    <given-names>Charles</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gibson</surname>
                    <given-names>Christopher J.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nag</surname>
                    <given-names>Anwesha</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thorner</surname>
                    <given-names>Aaron R.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0000-2829</contrib-id>
                  <name>
                    <surname>Wollison</surname>
                    <given-names>Bruce</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4478-1297</contrib-id>
                  <name>
                    <surname>Hansen</surname>
                    <given-names>Dennis Lund</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3088-4375</contrib-id>
                  <name>
                    <surname>Ellervik</surname>
                    <given-names>Christina</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                  <xref rid="aff8" ref-type="aff"/>
                  <xref rid="aff9" ref-type="aff"/>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>El Fassi</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                  <xref rid="aff11" ref-type="aff">11</xref>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de Stricker</surname>
                    <given-names>Karin</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ocias</surname>
                    <given-names>Lukas Frans</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6282-5348</contrib-id>
                  <name>
                    <surname>Brabrand</surname>
                    <given-names>Mette</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bjerrum</surname>
                    <given-names>Ole Weis</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Overgaard</surname>
                    <given-names>Ulrik Malthe</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Frederiksen</surname>
                    <given-names>Mikael</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kristensen</surname>
                    <given-names>Thomas Kielsgaard</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kruse</surname>
                    <given-names>Torben A.</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thomassen</surname>
                    <given-names>Mads</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mourits-Andersen</surname>
                    <given-names>Torben</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0996-1812</contrib-id>
                  <name>
                    <surname>Severinsen</surname>
                    <given-names>Marianne Tang</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stentoft</surname>
                    <given-names>Jesper</given-names>
                  </name>
                  <xref rid="aff20" ref-type="aff">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Starklint</surname>
                    <given-names>Joern</given-names>
                  </name>
                  <xref rid="aff21" ref-type="aff">21</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neuberg</surname>
                    <given-names>Donna S.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6767-0226</contrib-id>
                  <name>
                    <surname>Kjaer</surname>
                    <given-names>Lasse</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Larsen</surname>
                    <given-names>Thomas Stauffer</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3936-8032</contrib-id>
                  <name>
                    <surname>Hasselbalch</surname>
                    <given-names>Hans Carl</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff8" ref-type="aff">8</xref>
                  <xref rid="FM1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9822-806X</contrib-id>
                  <name>
                    <surname>Lindsley</surname>
                    <given-names>R. Coleman</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="FM1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9727-8495</contrib-id>
                  <name>
                    <surname>Mullally</surname>
                    <given-names>Ann</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="aff22" ref-type="aff">22</xref>
                  <xref rid="FM1" ref-type="author-notes">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Department of Hematology, Zealand University Hospital, Roskilde, Denmark;</aff>
              <aff id="aff2"><label>2</label>Department of Data Science, Dana-Farber Cancer Institute, Boston, MA;</aff>
              <aff id="aff3"><label>3</label>Division of Hematology, Brigham and Women's Hospital, Boston, MA;</aff>
              <aff id="aff4"><label>4</label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;</aff>
              <aff id="aff5"><label>5</label>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA;</aff>
              <aff id="aff6"><label>6</label>Department of Hematology, Odense University Hospital, Odense, Denmark;</aff>
              <aff id="aff7"><label>7</label>Department of Data and Innovation Support, Region Zealand, Soroe, Denmark;</aff>
              <aff id="aff8"><label>8</label>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;</aff>
              <aff id="aff9"><label>9</label>Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA;</aff>
              <aff id="aff10"><label>10</label>Department of Pathology, Harvard Medical School, Boston, MA;</aff>
              <aff id="aff11"><label>11</label>Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark;</aff>
              <aff id="aff12"><label>12</label>Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark;</aff>
              <aff id="aff13"><label>13</label>Department of Pathology, Odense University Hospital, Odense, Denmark;</aff>
              <aff id="aff14"><label>14</label>Statens Serum Institut, Copenhagen, Denmark;</aff>
              <aff id="aff15"><label>15</label>Department of Hematology, Hospital of Southern Jutland, Haderslev, Denmark;</aff>
              <aff id="aff16"><label>16</label>Department of Clinical Genetics, Odense University Hospital, Odense, Denmark;</aff>
              <aff id="aff17"><label>17</label>Department of Hematology, Hospital of South West Jutland, Esbjerg, Denmark;</aff>
              <aff id="aff18"><label>18</label>Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;</aff>
              <aff id="aff19"><label>19</label>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;</aff>
              <aff id="aff20"><label>20</label>Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;</aff>
              <aff id="aff21"><label>21</label>Department of Hematology, Holstebro Hospital, Holstebro, Denmark; and</aff>
              <aff id="aff22"><label>22</label>Broad Institute, Cambridge, MA</aff>
              <author-notes>
                <fn id="FM1" fn-type="equal">
                  <label>*</label>
                  <p>H.C.H., R.C.L., and A.M. contributed equally to this study.</p>
                </fn>
                <fn id="FM2" fn-type="other">
                  <p>Presented in abstract form at the 61st annual meeting of the American Society of Hematology, Orlando, FL, 7-10 December 2019.</p>
                </fn>
                <fn id="FM3" fn-type="other">
                  <p>Requests for data sharing may be made by contacting the corresponding author (Ann Mullally; e-mail: <email xlink:href="mailto:amullally@partners.org">amullally@partners.org</email>).</p>
                </fn>
                <corresp id="cor1">Correspondence: Ann Mullally, Harvard Institutes of Medicine Building, Room 738, 77 Ave Louis Pasteur, Boston, MA 02115; e-mail: <email xlink:href="mailto:ann_mullally@dfci.harvard.edu">ann_mullally@dfci.harvard.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <day>12</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>30</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>6</volume>
              <issue>7</issue>
              <fpage>2107</fpage>
              <lpage>2119</lpage>
              <history>
                <date date-type="received">
                  <day>29</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted-manuscript">
                  <day>10</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© 2022 by The American Society of Hematology. Licensed under <ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode" ext-link-type="uri">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)</ext-link>, permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</copyright-statement>
                <copyright-year>2022</copyright-year>
              </permissions>
              <self-uri xlink:href="advancesADV2021004856.pdf"/>
              <self-uri xlink:role="icon" xlink:href="advancesADV2021004856_thumb.jpg"/>
              <abstract abstract-type="precis">
                <title>Key Points</title>
                <p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Treatment with IFNÎ± was associated with distinct molecular responses in patients with <italic toggle="yes">JAK2</italic>-mutated MPN compared with <italic toggle="yes">CALR-</italic>mutated MPN.</p>
                    </list-item>
                    <list-item>
                      <p>Among patients treated with IFNÎ± who did not achieve CHR, <italic toggle="yes">DNMT3A</italic> mutations emerged more frequently than non-<italic toggle="yes">DNMT3A</italic> mutations.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Visual Abstract</title>
                <p>
                  <fig position="float" id="absf1" fig-type="featured">
                    <graphic xlink:href="advancesADV2021004856absf1" position="float"/>
                  </fig>
                </p>
              </abstract>
              <abstract>
                <title>Abstract</title>
                <p>Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing (NGS) on 202 pretreatment samples obtained from patients with MPN enrolled in the DALIAH trial (A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms; #NCT01387763), a randomized controlled phase 3 clinical trial, and 135 samples obtained after 24 months of therapy with recombinant interferon-alpha (IFNÎ±) or hydroxyurea. The primary aim was to evaluate the association between complete clinicohematologic response (CHR) at 24 months and molecular response through sequential assessment of 120 genes using NGS. Among <italic toggle="yes">JAK2</italic>-mutated patients treated with IFNÎ±, those with CHR had a greater reduction in the <italic toggle="yes">JAK2</italic> variant allele frequency (median, 0.29 to 0.07; <italic toggle="yes">P</italic> &lt; .0001) compared with those not achieving CHR (median, 0.27 to 0.14; <italic toggle="yes">P</italic> &lt; .0001). In contrast, the <italic toggle="yes">CALR</italic> variant allele frequency did not significantly decline in those achieving CHR or in those not achieving CHR. Treatment-emergent mutations in <italic toggle="yes">DNMT3A</italic> were observed more commonly in patients treated with IFNÎ± compared with hydroxyurea (<italic toggle="yes">P</italic> = .04). Furthermore, treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations were significantly enriched in IFNÎ±âtreated patients not attaining CHR (<italic toggle="yes">P</italic> = .02). A mutation in <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A,</italic> or <italic toggle="yes">ASXL1</italic> was significantly associated with prior stroke (age-adjusted odds ratio, 5.29; 95% confidence interval, 1.59-17.54; <italic toggle="yes">P</italic> = .007), as was a mutation in <italic toggle="yes">TET2</italic> alone (age-adjusted odds ratio, 3.03; 95% confidence interval, 1.03-9.01; <italic toggle="yes">P</italic> = .044). At 24 months, we found mutation-specific response patterns to IFNÎ±: (1) <italic toggle="yes">JAK2-</italic> and <italic toggle="yes">CALR</italic>-mutated MPN exhibited distinct molecular responses; and (2) <italic toggle="yes">DNMT3A-</italic>mutated clones/subclones emerged on treatment.</p>
              </abstract>
              <counts>
                <page-count count="13"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>Introduction</title>
              <p>Philadelphia chromosomeânegative chronic myeloproliferative neoplasms (MPNs) comprise essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), including prefibrotic myelofibrosis (Pre-MF). MPNs are clonal hematopoietic neoplasms characterized by excessive proliferation of mature hematopoietic cells from one or more of the myeloid lineages.<sup><xref rid="B1" ref-type="bibr">1,2</xref></sup> The diseases are associated with an increased risk of thrombohemorrhagic events and reduced life expectancy compared with the general population.<sup><xref rid="B3" ref-type="bibr">3,4</xref></sup> ET and PV may progress into post-ET and post-PV myelofibrosis, and all disease entities may transform into secondary acute myeloid leukemia, which has a dismal prognosis.<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p>
              <p>The majority of MPNs are driven by somatic mutations in <italic toggle="yes">JAK2</italic>, <italic toggle="yes">CALR</italic>, or <italic toggle="yes">MPL</italic> that arise in the hematopoietic stem cell compartment (ie, MPN phenotypic driver mutations).<sup><xref rid="B6" ref-type="bibr">6</xref></sup> All 3 MPN phenotypic driver mutations lead to uncontrolled myeloproliferation by constitutive activation of the JAK-STAT signal transduction pathway through ligand-independent activation and hypersensitivity of type I cytokine receptors.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Approximately 95% to 97% of patients with PV and 50% to 60% of patients with ET or PMF harbor a point mutation in exon 14 of the <italic toggle="yes">JAK2</italic> gene.<sup><xref rid="B8" ref-type="bibr">8-11</xref></sup> The remaining 2% to 3% of patients with PV carry mutations in <italic toggle="yes">JAK2</italic> exon 12.<sup><xref rid="B12" ref-type="bibr">12</xref></sup>
<italic toggle="yes">CALR</italic> or <italic toggle="yes">MPL</italic> mutations are present in the majority of patients with <italic toggle="yes">JAK2</italic>-negative ET and PMF. Approximately 10% of patients with MPN carry none of the 3 phenotypic driver mutations and are referred to as âtriple-negative.â<sup><xref rid="B13" ref-type="bibr">13,14</xref></sup></p>
              <p>The emergence of next-generation sequencing (NGS) has expanded insights into the molecular complexity of MPN, and &gt;50 genes have been reported to be recurrently mutated.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Mutations outside of <italic toggle="yes">JAK2</italic>, <italic toggle="yes">CALR</italic>, and <italic toggle="yes">MPL</italic> (ie, concomitant somatic mutations) are observed in &gt;50% of patients with MPN, and increasing numbers are observed with disease progression.<sup><xref rid="B16" ref-type="bibr">16,17</xref></sup> The most common classes of concomitant mutations consist of genes involved in DNA methylation (<italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A, IDH1</italic>, and <italic toggle="yes">IDH2</italic>), chromatin modification (<italic toggle="yes">ASXL1</italic> and <italic toggle="yes">EZH2</italic>), RNA splicing (<italic toggle="yes">SRSF2</italic>, <italic toggle="yes">U2AF1</italic>, <italic toggle="yes">SF3B1</italic>, and <italic toggle="yes">ZRSR2</italic>), signaling pathways (<italic toggle="yes">LNK</italic>/S<italic toggle="yes">H2B3</italic>, <italic toggle="yes">CBL</italic>, <italic toggle="yes">NRAS</italic>, <italic toggle="yes">KRAS</italic>, and <italic toggle="yes">PTPN1</italic>), transcription factors (<italic toggle="yes">RUNX1</italic> and <italic toggle="yes">NFE2</italic>), and DNA damage response/stress signaling (<italic toggle="yes">TP53</italic> and <italic toggle="yes">PPM1D</italic>).<sup><xref rid="B7" ref-type="bibr">7</xref></sup> These mutations may precede the acquisition of the phenotypic driver mutation or occur subsequently in the same or a different clone.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> Concomitant mutations may contribute to phenotype and are often associated with disease progression and inferior survival.<sup><xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B18" ref-type="bibr">18-20</xref></sup> Furthermore, the presence of specific concomitant mutations,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> as well as the total number<sup><xref rid="B19" ref-type="bibr">19</xref></sup> and order of acquisition, influences prognosis.<sup><xref rid="B21" ref-type="bibr">21</xref></sup></p>
              <p>Internationally, the most widely used first-line cytoreductive therapy in patients with high-risk ET or PV is hydroxyurea (HU). HU effectively reduces elevated peripheral blood counts and the risk of thrombosis.<sup><xref rid="B22" ref-type="bibr">22-24</xref></sup> However, there is conflicting evidence regarding the potential of HU to induce a continuous reduction of the <italic toggle="yes">JAK2V7617F</italic>-mutated clone.<sup><xref rid="B25" ref-type="bibr">25-27</xref></sup> In contrast, recombinant interferon-Î± (IFNÎ±), which has been used off-label for the treatment of MPN for &gt;3 decades, has been associated with molecular responses in <italic toggle="yes">JAK2V617F</italic>-mutated MPN.<sup><xref rid="B28" ref-type="bibr">28-36</xref></sup> A subset of patients achieve molecular remissions and normalization of the bone marrow after long-term treatment, which may be sustained in a minority of patients even after treatment discontinuation, an effect never observed for HU.<sup><xref rid="B36" ref-type="bibr">36-39</xref></sup></p>
              <p>Increasing knowledge regarding the complex molecular landscape of MPN has enabled more accurate personalized prediction of outcomes and improved clinical decision-making, particularly in myelofibrosis. However, the predictive role of somatic mutations regarding response and resistance to cytoreductive therapy remains unclear. To address this question, we performed serial genomic profiling on patients enrolled in the DALIAH trial (A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms), which to our knowledge is the largest randomized controlled phase 3 trial of IFNÎ± vs HU in patients with newly diagnosed MPN.</p>
            </sec>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Trial design</title>
                <p>Genomic profiling by NGS was performed in 202 pretreatment samples and 135 samples obtained after 24 months from patients enrolled in the DALIAH trial. This study was an investigator-initiated, open-label, randomized controlled, parallel-design, clinical phase 3 trial (ClinicalTrials.gov identifier: #NCT01387763). The study was approved by the Danish Regional Science Ethics Committee and the Danish Medicines Agency and was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice. All study participants provided written informed consent before entering the trial.</p>
                <p>Patients aged â¥18 years with a diagnosis of ET, PV, Pre-MF, or PMF according to the World Health Organization 2008 criteria<sup><xref rid="B40" ref-type="bibr">40</xref></sup> and evidence of active disease regardless of risk group were eligible to be enrolled. Detailed inclusion and exclusion criteria are provided in the supplemental Methods. Patients aged &gt;60 years were randomly allocated (1:1:1) to receive HU, IFNÎ±-2a, or IFNÎ±-2b; patients aged â¤60 years were randomly allocated (1:1) to receive IFNÎ±-2a or IFNÎ±-2b. Treatment dose was modified based on efficacy and toxicity according to predefined dose levels (supplemental Tables 1 and 2). Clinicohematologic response (CHR) assessment was performed by central review according to the modified 2009 European LeukemiaNet (ET, PV, and Pre-MF)<sup><xref rid="B41" ref-type="bibr">41</xref></sup> and the 2005 European Myelofibrosis Network criteria (PMF).<sup><xref rid="B42" ref-type="bibr">42</xref></sup></p>
              </sec>
              <sec>
                <title>NGS analysis</title>
                <p>Genomic profiling comprised targeted NGS of 120 myeloid malignancyâassociated genes and 1609 informative single nucleotide polymorphisms on chromosome 9p. Detailed information on the sequencing, including a list of sequenced genes and genomic coordinates of all target regions, is provided in the supplemental Methods and supplemental Tables 6 to 8.</p>
              </sec>
              <sec>
                <title>Statistical methods</title>
                <p>Statistical methods are presented in the supplemental Methods.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Clinical characteristics at baseline</title>
                <p>NGS was performed on 202 pretreatment samples from patients randomly allocated to treatment with HU (n = 38) or IFNÎ±-2a (n = 164), and 135 samples were obtained 24 months after initiation of therapy (HU, n = 34; IFNÎ±, n = 101) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Seventy-two patients (36%) had ET, 89 (44%) had PV, 16 (8%) had Pre-MF, and 25 (12%) had PMF (<xref rid="T1" ref-type="table">Table 1</xref>). The median age was 62 years (range, 20-88 years), and 112 (55%) were male. Thirty-nine (19%) patients had experienced previous major thrombosis, including 17 (8%) with prior stroke (ET, 4 of 72 [6%]; PV, 10 of 89 [11%]; Pre-MF, 1 of 16 [6%]; PMF, 2 of 25 [8%]). Twenty-one (10%) patients received HU from screening and until random allocation in the study due to major thrombosis at diagnosis or platelet count &gt;1000 Ã 10<sup>9</sup>/L at screening. The median time from screening to randomization in these patients was 21 days (range, 3-45 days). Prior phlebotomy was performed in 90 (45%) patients, with a median number of 3 phlebotomies in each patient (range, 1-29). Due to the design of the study, median age was higher in patients allocated to receive HU (68 years; interquartile range [IQR], 64-71 years) compared with IFNÎ± (59 years; IQR, 46-67 years). Baseline demographic and clinical characteristics are presented in <xref rid="T1" ref-type="table">Table 1</xref> and supplemental Tables 9 and 10.</p>
                <fig position="float" id="F1">
                  <label>Figure 1.</label>
                  <caption>
                    <p><bold>Trial flowchart.</bold> NGS was performed on 202 primary MPN samples and 135 samples obtained 24 months after initiation of therapy with either HU or IFNÎ± (IFNÎ±-2a or IFNÎ±-2b). One patient allocated to IFN-Î± died within 24 months.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021004856f1" position="float"/>
                </fig>
                <table-wrap position="float" id="T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>
Baseline demographic and clinical characteristics according to treatment group
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead valign="bottom">
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">HU (n = 38)</th>
                        <th align="center" rowspan="1" colspan="1">IFNÎ±-2a (n = 82)</th>
                        <th align="center" rowspan="1" colspan="1">IFNÎ±-2b (n = 82)</th>
                        <th align="center" rowspan="1" colspan="1">Total (n = 202)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Patient-related variable</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âMPN subtype</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââET</td>
                        <td align="center" rowspan="1" colspan="1">9 (24)</td>
                        <td align="center" rowspan="1" colspan="1">30 (37)</td>
                        <td align="center" rowspan="1" colspan="1">33 (40)</td>
                        <td align="center" rowspan="1" colspan="1">72 (36)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââPV</td>
                        <td align="center" rowspan="1" colspan="1">21 (55)</td>
                        <td align="center" rowspan="1" colspan="1">34 (41)</td>
                        <td align="center" rowspan="1" colspan="1">34 (41)</td>
                        <td align="center" rowspan="1" colspan="1">89 (44)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââPre-MF</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">9 (11)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">16 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââPMF</td>
                        <td align="center" rowspan="1" colspan="1">7 (18)</td>
                        <td align="center" rowspan="1" colspan="1">9 (11)</td>
                        <td align="center" rowspan="1" colspan="1">9 (11)</td>
                        <td align="center" rowspan="1" colspan="1">25 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âAge, median (range), y</td>
                        <td align="center" rowspan="1" colspan="1">68 (60-80)</td>
                        <td align="center" rowspan="1" colspan="1">60 (21-88)</td>
                        <td align="center" rowspan="1" colspan="1">58 (20-81)</td>
                        <td align="center" rowspan="1" colspan="1">62 (20-88)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âAge group</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââ â¤60 y</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">45 (55)</td>
                        <td align="center" rowspan="1" colspan="1">45 (55)</td>
                        <td align="center" rowspan="1" colspan="1">90 (45)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââ&gt;60 y</td>
                        <td align="center" rowspan="1" colspan="1">38 (100)</td>
                        <td align="center" rowspan="1" colspan="1">37 (45)</td>
                        <td align="center" rowspan="1" colspan="1">37 (45)</td>
                        <td align="center" rowspan="1" colspan="1">112 (55)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âBiological sex</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââFemale</td>
                        <td align="center" rowspan="1" colspan="1">14 (37)</td>
                        <td align="center" rowspan="1" colspan="1">37 (45)</td>
                        <td align="center" rowspan="1" colspan="1">39 (48)</td>
                        <td align="center" rowspan="1" colspan="1">90 (45)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââMale</td>
                        <td align="center" rowspan="1" colspan="1">24 (63)</td>
                        <td align="center" rowspan="1" colspan="1">45 (55)</td>
                        <td align="center" rowspan="1" colspan="1">43 (52)</td>
                        <td align="center" rowspan="1" colspan="1">112 (55)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHistory of major thrombosis</td>
                        <td align="center" rowspan="1" colspan="1">6 (16)</td>
                        <td align="center" rowspan="1" colspan="1">21 (25)</td>
                        <td align="center" rowspan="1" colspan="1">12 (15)</td>
                        <td align="center" rowspan="1" colspan="1">39 (19)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHistory of prior stroke</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">10 (12)</td>
                        <td align="center" rowspan="1" colspan="1">4 (5)</td>
                        <td align="center" rowspan="1" colspan="1">17 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âPhenotypic driver mutation</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">ââJAK2<xref rid="tblfn2" ref-type="table-fn">*</xref></italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">31 (84)</td>
                        <td align="center" rowspan="1" colspan="1">62 (80)</td>
                        <td align="center" rowspan="1" colspan="1">57 (80)</td>
                        <td align="center" rowspan="1" colspan="1">150 (74)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">ââCALR</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">6 (16)</td>
                        <td align="center" rowspan="1" colspan="1">10 (14)</td>
                        <td align="center" rowspan="1" colspan="1">13 (17)</td>
                        <td align="center" rowspan="1" colspan="1">29 (14)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">ââMPL</italic>
                          <xref rid="tblfn3" ref-type="table-fn">â </xref>
                        </td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">4 (6)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">10 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ââTriple-negative</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">4 (5)</td>
                        <td align="center" rowspan="1" colspan="1">11 (12)</td>
                        <td align="center" rowspan="1" colspan="1">16 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Disease-related variable</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHemoglobin, mmol/L</td>
                        <td align="center" rowspan="1" colspan="1">9.3 (7.9-10.2)</td>
                        <td align="center" rowspan="1" colspan="1">9.0 (8.3-9.9)</td>
                        <td align="center" rowspan="1" colspan="1">8.9 (8.1-9.5)</td>
                        <td align="center" rowspan="1" colspan="1">9.0 (8.2-9.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHematocrit, vol %</td>
                        <td align="center" rowspan="1" colspan="1">45 (41-52)</td>
                        <td align="center" rowspan="1" colspan="1">45 (42-47)</td>
                        <td align="center" rowspan="1" colspan="1">43 (40-47)</td>
                        <td align="center" rowspan="1" colspan="1">44 (41-49)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âWBC, Ã10<sup>9</sup>/L</td>
                        <td align="center" rowspan="1" colspan="1">9.9 (8.1-11.5)</td>
                        <td align="center" rowspan="1" colspan="1">8.9 (7.6-11.6)</td>
                        <td align="center" rowspan="1" colspan="1">9.5 (7.8-12.7)</td>
                        <td align="center" rowspan="1" colspan="1">9.4 (7.7-11.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âPlatelets, Ã10<sup>9</sup>/L</td>
                        <td align="center" rowspan="1" colspan="1">664 (552-895)</td>
                        <td align="center" rowspan="1" colspan="1">712 (480-930)</td>
                        <td align="center" rowspan="1" colspan="1">615 (484-852)</td>
                        <td align="center" rowspan="1" colspan="1">667 (502-904)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âLactate dehydrogenase, U/L</td>
                        <td align="center" rowspan="1" colspan="1">242 (216-288)</td>
                        <td align="center" rowspan="1" colspan="1">232 (180-296)</td>
                        <td align="center" rowspan="1" colspan="1">224 (177-294)</td>
                        <td align="center" rowspan="1" colspan="1">229 (184-294)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âSplenomegaly on imaging, â¥13 cm</td>
                        <td align="center" rowspan="1" colspan="1">15/30 (50)</td>
                        <td align="center" rowspan="1" colspan="1">21/50 (42)</td>
                        <td align="center" rowspan="1" colspan="1">31/60 (52)</td>
                        <td align="center" rowspan="1" colspan="1">67/140 (48)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDisease-related symptoms<xref rid="tblfn4" ref-type="table-fn">â¡</xref></td>
                        <td align="center" rowspan="1" colspan="1">19 (50)</td>
                        <td align="center" rowspan="1" colspan="1">51 (62)</td>
                        <td align="center" rowspan="1" colspan="1">40 (49)</td>
                        <td align="center" rowspan="1" colspan="1">110 (54)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Pretreatment</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHU</td>
                        <td align="center" rowspan="1" colspan="1">4 (11)</td>
                        <td align="center" rowspan="1" colspan="1">10 (12)</td>
                        <td align="center" rowspan="1" colspan="1">7 (9)</td>
                        <td align="center" rowspan="1" colspan="1">21 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âPhlebotomy</td>
                        <td align="center" rowspan="1" colspan="1">17 (45)</td>
                        <td align="center" rowspan="1" colspan="1">34 (41)</td>
                        <td align="center" rowspan="1" colspan="1">39 (48)</td>
                        <td align="center" rowspan="1" colspan="1">90 (45)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>Data are presented as no. (%) or median (IQR) unless otherwise indicated.</p>
                    </fn>
                    <fn id="tblfn2">
                      <label>*</label>
                      <p>Mutated <italic toggle="yes">JAK2V617F</italic> or <italic toggle="yes">JAK2</italic> exon 12 mutation.</p>
                    </fn>
                    <fn id="tblfn3">
                      <label>â </label>
                      <p>Coexistence of mutated <italic toggle="yes">MPL</italic> and <italic toggle="yes">JAK2V617F</italic> was detected in 3 patients.</p>
                    </fn>
                    <fn id="tblfn4">
                      <label>â¡</label>
                      <p>Constitutional symptoms, microcirculatory disturbances, or pruritus.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Somatic mutations at baseline</title>
                <p>Somatic mutations in 34 genes were detected by NGS in 191 (95%) patients at baseline. MPN phenotypic driver mutations were present in 92% of the patients: <italic toggle="yes">JAK2</italic> (74%; <italic toggle="yes">JAK2V617F</italic>, 73%; <italic toggle="yes">JAK2</italic> exon 12, 1%), <italic toggle="yes">CALR</italic> (14%; type 1, 11%; type 2, 3%), or <italic toggle="yes">MPL</italic> (5%) (<xref rid="F2" ref-type="fig">Figure 2</xref>; supplemental Table 11). No somatic mutations were detected in 11 patients (5%), 1 mutation was detected in 88 patients (44%), 2 mutations in 55 patients (27%), and â¥3 mutations in 48 patients (24%). The number of mutations was significantly different based on diagnosis (mean number Â± standard deviation of mutations in ET, 1.6 Â± 1.5; PV, 2.0 Â± 1.3; Pre-MF, 2.1 Â± 1.2; PMF, 1.9 Â± 1.9). Although the presence of phenotypic driver mutations is usually considered mutually exclusive, we found coexistence of <italic toggle="yes">JAK2V617F</italic> and <italic toggle="yes">MPL</italic> mutations in 3 patients (1%). Sixteen (8%) patients (ET, n = 12; PV, n = 2; Pre-MF, n = 1; PMF, n = 1) were triple-negative for <italic toggle="yes">JAK2</italic>, <italic toggle="yes">CALR</italic>, and <italic toggle="yes">MPL</italic> mutations. The median <italic toggle="yes">JAK2</italic> variant allele frequency (VAF) at baseline was 0.25 (range, 0.01-0.94), and <italic toggle="yes">JAK2</italic> uniparental disomy (<italic toggle="yes">JAK2-</italic>UPD) was observed in 28%. The median <italic toggle="yes">JAK2</italic> VAF was significantly higher among patients with <italic toggle="yes">JAK2</italic>-UPD (0.48; IQR, 0.35-0.68) compared with those without <italic toggle="yes">JAK2</italic>-UPD (0.15; IQR, 0.09-0.26; <italic toggle="yes">P</italic> &lt; .0001). The most frequent concomitant mutations at baseline affected 3 genes: <italic toggle="yes">TET2</italic> (24%), <italic toggle="yes">DNMT3A</italic> (16%), and <italic toggle="yes">ASXL1</italic> (10%). Spliceosome gene mutations were found in 4% (<italic toggle="yes">SF3B1</italic>, n = 6; <italic toggle="yes">SRSF2</italic>, n = 2; <italic toggle="yes">U2AF1</italic>, n = 1; <italic toggle="yes">ZRSR2</italic>, n = 1), and mutations involving RAS/MAPK signaling, including <italic toggle="yes">CBL, KRAS</italic>, <italic toggle="yes">NRAS</italic>, <italic toggle="yes">NF1, PTPN11</italic>, and <italic toggle="yes">RIT1</italic>, were detected in 6%.</p>
                <fig position="float" id="F2">
                  <label>Figure 2.</label>
                  <caption>
                    <p><bold>Genomic profiling of somatic mutations in baseline samples by NGS (comutation plot).</bold> Each column represents 1 patient (n = 202), and the rows represent different somatic mutations. The VAF for each phenotypic driver mutation is color coded. The frequency of specific somatic mutations is listed on the right border of the figure. Somatic mutations in 34 different genes were detected in 191 (95%) patients, including 92% with MPN phenotypic driver mutations: <italic toggle="yes">JAK2</italic>, 74%; <italic toggle="yes">CALR</italic>, 14%; or <italic toggle="yes">MPL</italic>, 5%. <italic toggle="yes">JAK2-</italic>UPD was observed in 28% and was significantly associated with PV (Kruskal-Wallis test, <italic toggle="yes">P</italic> &lt; .0001). The most frequent concomitant mutations affected 3 genes: <italic toggle="yes">TET2</italic> (24%), <italic toggle="yes">DNMT3A</italic> (16%), and <italic toggle="yes">ASXL1</italic> (10%). 9p-UPD, uniparental disomy of chromosome 9p.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021004856f2" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Association between somatic mutations and clinical characteristics at baseline</title>
                <p>At baseline, mutations in <italic toggle="yes">JAK2</italic> were detected in 98% of patients with PV and 53%, 69%, and 56% of patients with ET, Pre-MF, and PMF, respectively. <italic toggle="yes">JAK2</italic>-UPD was most commonly found in patients with PV (54%) (<xref rid="F2" ref-type="fig">Figure 2</xref>), where it was significantly associated with higher hemoglobin level (<italic toggle="yes">P</italic> = .0003), higher hematocrit level (<italic toggle="yes">P</italic> &lt; .0001), higher neutrophil count (<italic toggle="yes">P</italic> = .039), and lower platelet count (<italic toggle="yes">P</italic> &lt; .0001) compared with PV patients without <italic toggle="yes">JAK2</italic>-UPD (supplemental Table 12). <italic toggle="yes">JAK2</italic>-UPD was not detected in any patients with ET. Among patients with ET, Pre-MF, and PMF, patients with ET were more likely to present with triple-negative disease (ET, 18%; PV, 2%; Pre-MF, 6%; PMF, 4%; <italic toggle="yes">P</italic> = .007), which was significantly associated with younger age compared with patients harboring 1 of the 3 phenotypic driver mutations (median, 44 years vs 64 years; <italic toggle="yes">P</italic> = .006). Among patients with ET, Pre-MF, and PMF, mutated <italic toggle="yes">CALR</italic> was significantly associated with higher platelet count (<italic toggle="yes">P</italic> = .004) or elevated lactate dehydrogenase levels (<italic toggle="yes">P</italic> = .0008) compared with patients with <italic toggle="yes">JAK2</italic> (<sup>+/â</sup><italic toggle="yes">MPL</italic>)-mutated MPN or patients with triple-negative MPN (supplemental Table 13).</p>
                <p>The most frequent concomitant mutations (ie, in <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">ASXL1</italic>, RAS/MAPK signaling, and RNA splicing genes) among all MPN subtypes were detected in both <italic toggle="yes">JAK2</italic>-mutated and <italic toggle="yes">JAK2</italic> wild-type (WT) patients. However, coexistence of <italic toggle="yes">ASXL1</italic> was significantly associated with <italic toggle="yes">JAK2</italic>, as it was present in 13% of <italic toggle="yes">JAK2</italic>-mutated patients compared with 2% of <italic toggle="yes">JAK2</italic> WT patients (<italic toggle="yes">P</italic> = .029) (supplemental Table 14). Mutations in <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A</italic>, or <italic toggle="yes">ASXL1</italic> were significantly associated with older age (â¥60 years) (54% vs 26%; <italic toggle="yes">P</italic> &lt; .0001), as well as with a history of major thrombosis (odds ratio [OR], 2.11 [95% confidence interval (CI), 1.04-4.37; <italic toggle="yes">P</italic> = .038]; age-adjusted OR, 1.96 [95% CI, 0.94-4.12; <italic toggle="yes">P</italic> = .073]) and in particular prior stroke (OR, 5.21 [95% CI, 1.64-16.67; <italic toggle="yes">P</italic> = .005]; age-adjusted OR, 5.29 [95% CI, 1.59-17.54; <italic toggle="yes">P</italic> = .007]) compared with patients without these mutations. Also, <italic toggle="yes">TET2</italic> alone was significantly associated with prior stroke (age-adjusted OR, 3.03; 95% CI, 1.03-9.01; <italic toggle="yes">P</italic> = .044). No other significant baseline associations were detected between clinical characteristics and baseline mutational status.</p>
              </sec>
              <sec>
                <title>Treatment discontinuation within 24 months</title>
                <p>At 24 months, 40% of all patients had discontinued study medication (supplemental Table 15). The most frequent reason for treatment discontinuation across all treatment groups was treatment-related toxicity: HU, 8%; IFNÎ±-2a, 30%; and IFNÎ±-2b, 38%. One patient with <italic toggle="yes">CALR-</italic>positive PMF and a history of chronic obstructive pulmonary disease died of pneumonia after â¼17 months of treatment with IFNÎ±-2b. None of the patients transformed to post-ET/PV myelofibrosis or secondary acute myeloid leukemia.</p>
              </sec>
              <sec>
                <title>CHR at 24 months</title>
                <p>At 24 months, 121 patients were on study medication and eligible for CHR assessment. Missing data made response evaluation impossible in 3 of these patients. CHR was achieved in 21% (95% CI, 10-37) treated with HU and 26% (95% CI, 19-33) treated with IFNÎ± (IFNÎ±-2a, 30%; IFNÎ±-2b, 21%) (<italic toggle="yes">P</italic> = .68) (<xref rid="F3" ref-type="fig">Figure 3A-B</xref>; supplemental Table 16). Median time to CHR was 5.7 months (IQR, 1.8-10.5 months) for HU, 4.9 months (IQR, 2.1-8.9 months) for IFNÎ±-2a, and 6.0 months (IQR, 1.8-10.1 months) for IFNÎ±-2b. Of note, 31 (19%) patients allocated to receive IFNÎ± received either pretreatment with HU (n = 17) and/or combination treatment with IFNÎ± and HU (n = 28) within 24 months after treatment allocation (supplemental Table 17). At CHR assessment at 24 months, 7 patients (HU, n = 1; IFNÎ±, n = 6) received combination treatment. The median duration of combination treatment among these patients was 14.3 months (range, 6.2-18.4 months). Two were in CHR, 1 was not evaluable due to missing data, and 4 were nonresponders.</p>
                <fig position="float" id="F3">
                  <label>Figure 3.</label>
                  <caption>
                    <p><bold>Complete CHR response at 24 months.</bold> (A) Proportion of patients with complete CHR over time according to treatment group. Median time to CHR was 5.7 months (IQR, 1.8-10.5 months) for HU, and 4.9 months (IQR, 2.1-8.9 months) and 6.0 months (IQR, 1.8-10.1 months) for patients treated with IFNÎ±-2a or IFNÎ±-2b, respectively. The CHR rate reached a maximum after 12 months among patients treated with HU (47%), whereas the CHR rate increased almost gradually over time among patients treated with IFNÎ±-2a or IFNÎ±-2b. (B) Proportion of patients with CHR at 24 months according to treatment group. CHR was achieved in 8 of 38 (21%; 95% CI, 10-37) patients treated with HU, 25 of 82 (30%; 95% CI, 21-42) patients treated with IFNÎ±-2a, and in 17 of 82 (17%; 95% CI, 13-31) patients treated with IFNÎ±-2b. No significant difference in the CHR rate was detected between HU and the two IFNÎ± groups combined. Patients considered nonevaluable (NE) at 24 months had all discontinued the study therapy to which they were allocated, except 3 patients in whom complete diagnostic workup was not available at 24 months (HU, n = 1; IFNÎ±-2a, n = 2). Error bars are 95% CI upper limits.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021004856f3" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Somatic mutations on serial sampling</title>
                <p>NGS was performed in 135 patients at 24 months, including 113 of 121 patients eligible for CHR assessment (HU, n = 32; IFNÎ±, n = 84) and in 19 who had discontinued study treatment (HU, n = 2; IFNÎ±, n = 17) (supplemental Figure 2). Phenotypic driver mutations remained detectable by NGS at 24 months in all patients. <italic toggle="yes">JAK2</italic> VAF decreased in 94% of the patients treated with IFNÎ± and in 75% treated with HU (<italic toggle="yes">P</italic> = .01). The median absolute <italic toggle="yes">JAK2</italic> VAF reduction (baseline to 24 months) was significantly greater in patients treated with IFNÎ± (HU 0.05 vs IFNÎ± 0.11; <italic toggle="yes">P</italic> = .005). The change in <italic toggle="yes">CALR</italic> VAF with treatment was more heterogeneous. The <italic toggle="yes">CALR</italic> VAF decreased in 80% of patients allocated to HU and 78% allocated to IFNÎ± (<italic toggle="yes">P</italic> = .99) (median VAF reduction, HU 0.02 vs IFNÎ± 0.04; <italic toggle="yes">P</italic> = .63) (supplemental Table 16). Among patients treated with IFNÎ±, those with <italic toggle="yes">JAK2</italic>-UPD had a greater absolute <italic toggle="yes">JAK2</italic> VAF reduction (median, 0.49 to 0.17) compared with those without <italic toggle="yes">JAK2</italic>-UPD (median, 0.15 to 0.08) (<italic toggle="yes">P</italic> &lt; .0001). No significant reduction in <italic toggle="yes">JAK2</italic> VAF was observed among patients with <italic toggle="yes">JAK2</italic>-UPD treated with HU (median, 0.44 to 0.30) than those without <italic toggle="yes">JAK2</italic>-UPD (median, 0.22 to 0.08) (<italic toggle="yes">P</italic> = .76).</p>
                <p>Mutations were detected in 30 genes at 24 months, including 3 not observed at baseline (<italic toggle="yes">EP300</italic>, <italic toggle="yes">IDH2</italic>, and <italic toggle="yes">PHF6</italic>) (supplemental Figure 2). Thirty-eight treatment-emergent mutations were detected in 32 patients (HU, n = 14; IFNÎ±, n = 18), of whom 4 patients had discontinued treatment.</p>
                <p><italic toggle="yes">DNMT3A</italic> was the most frequent treatment-emergent mutation (n = 15 [39%]), followed by <italic toggle="yes">TET2</italic> (n = 4 [11%]), <italic toggle="yes">ASXL1</italic> (n = 3 [8%]), <italic toggle="yes">PPM1D</italic> (n = 3 [8%]), and <italic toggle="yes">TP53</italic> (n = 3 [8%]) (<xref rid="F4" ref-type="fig">Figure 4A</xref>; supplemental Table 18). The VAF of treatment-emergent mutations was low (median, 1.5%), and they primarily occurred in <italic toggle="yes">JAK2</italic>-positive patients (97%) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). The NGS platform enabled simultaneous evaluation of the following: (1) the molecular response of MPN phenotypic driver mutations; (2) <italic toggle="yes">JAK2</italic>-UPD at 9p; and (3) detection of treatment-emergent mutations in any of the &gt;100 genes assessed, allowing us to uncover the complexity of molecular responses (<xref rid="F4" ref-type="fig">Figure 4C-D</xref>). Treatment-emergent mutations in <italic toggle="yes">DNMT3A</italic> were more commonly observed in patients treated with IFNÎ± (11 of 18 [61%]) than HU (3 of 14 [21%]) (<italic toggle="yes">P</italic> = .046). In contrast, treatment-emergent mutations in <italic toggle="yes">PPM1D</italic> or <italic toggle="yes">TP53</italic> were more common in patients who received HU (5 of 14 [36%]) compared with IFNÎ± (1 of 18 [6%]) (<italic toggle="yes">P</italic> = .06) (supplemental Figure 3).</p>
                <fig position="float" id="F4">
                  <label>Figure 4.</label>
                  <caption>
                    <p><bold>Treatment-emergent mutations at 24 months.</bold> (A) Number of treatment-emergent mutations at 24 months. Thirty-eight treatment-emergent mutations were detected in 32 patients, 4 of whom had discontinued treatment. Mutations were defined as treatment-emergent if: (1) the VAF was &lt;0.01 in the baseline sample and â¥0.01 in the 24-month sample (n = 36); or (2) if the VAF was â¥0.01 in the baseline sample and had a more than fourfold increase in the 24-month sample (n = 2). The most frequent treatment-emergent mutations were detected in <italic toggle="yes">DNMT3A</italic> (n = 15 [39%]), followed by <italic toggle="yes">TET2</italic> (n = 4 [11%]), <italic toggle="yes">ASXL1</italic> (n = 3 [8%]), <italic toggle="yes">PPM1D</italic> (n = 3 [8%]), and <italic toggle="yes">TP53</italic> (n = 3 [8%]). (B) VAF of treatment-emergent mutations at baseline and posttreatment at 24 months. The median VAF of treatment-emergent mutations was low (median, 1.5%) and primarily occurred in <italic toggle="yes">JAK2</italic>-mutated patients (97%). Representative examples of treatment-emergent mutations detected in patients treated with HU (C) and IFNÎ± (D). MPN phenotypic driver mutations are depicted with blue lines, treatment-emergent concomitant mutations with red lines, and other concomitant mutations with black lines. The upper rows of panels C and D also show uniparental disomy of chromosome 9p (9p-UPD) analysis. In all examples, 9p-UPD is no longer detectable posttreatment at 24 months, which is concordant with the decrease in mutant <italic toggle="yes">JAK2</italic> VAF.</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021004856f4" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Association between somatic mutations and complete CHR on serial sampling</title>
                <p>The probability of CHR at 24 months was not associated with <italic toggle="yes">JAK2</italic> (<italic toggle="yes">P</italic> = .27), <italic toggle="yes">JAK2</italic>-UPD (<italic toggle="yes">P</italic> = .35), or <italic toggle="yes">CALR</italic> (<italic toggle="yes">P</italic> = .10) baseline mutational status or concomitant mutations in <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">TET2</italic>, or <italic toggle="yes">ASXL1</italic> (<italic toggle="yes">P</italic> = .40) in the entire cohort or when stratifying according to treatment group (HU vs IFNÎ±). Analysis for associations with other concomitant mutations was not feasible due to their low frequency in the cohort. CHR at 24 months was obtained in 34 (23%) of 150 patients with <italic toggle="yes">JAK2</italic> mutations, 11 (37%) of 29 patients with <italic toggle="yes">CALR</italic> mutations, and in 18 (21%) of 84 patients with <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">TET2</italic>, or <italic toggle="yes">ASXL1</italic> mutations. The <italic toggle="yes">JAK2</italic> VAF declined significantly in patients randomized to receive HU achieving CHR (median, 0.25 to 0.08; <italic toggle="yes">P</italic> = .03) but not in those not achieving CHR (median, 0.30 to 0.26; <italic toggle="yes">P</italic> = .10). Among <italic toggle="yes">JAK2</italic>-positive patients randomized to receive IFNÎ±, those attaining CHR had a greater reduction in the <italic toggle="yes">JAK2</italic> VAF (median, 0.29 to 0.07; <italic toggle="yes">P</italic> &lt; .0001) compared with patients who did not achieve CHR (median, 0.27 to 0.14; <italic toggle="yes">P</italic> &lt; .0001) (<xref rid="F5" ref-type="fig">Figure 5A</xref>). In contrast, the mutant <italic toggle="yes">CALR</italic> VAF did not significantly decline in either those achieving CHR during treatment with IFNÎ± (median, 0.17 to 0.13; <italic toggle="yes">P</italic> = .078) or in those not achieving CHR (median, 0.21 to 0.17; <italic toggle="yes">P</italic> = .066) (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Of note, only 18 <italic toggle="yes">CALR</italic>-positive patients allocated to receive IFNÎ± were evaluable for response at 24 months. None of the 5 <italic toggle="yes">CALR</italic>-positive patients allocated to receive HU achieved CHR.</p>
                <fig position="float" id="F5">
                  <label>Figure 5.</label>
                  <caption>
                    <p><bold>Association between somatic mutations and complete CHR on serial sampling.</bold> (A-B) Molecular response among patients allocated to IFNÎ± at baseline (Pre) and at 24 months (Post) of treatment by complete CHR. (A) Among <italic toggle="yes">JAK2-</italic>mutated patients, those attaining CHR at 24 months had a greater reduction in the <italic toggle="yes">JAK2</italic> VAF (median, 0.29 to 0.07; <italic toggle="yes">P</italic> &lt; .0001) compared with <italic toggle="yes">JAK2</italic>-mutated patients who did not achieve CHR (median, 0.27 to 0.14; <italic toggle="yes">P</italic> &lt; .0001). (B) The <italic toggle="yes">CALR</italic> VAF did not significantly decline among patients achieving CHR nor among those not achieving CHR at 24 months. The middle horizontal lines indicate the median value; box limits indicate the 5th and 95th percentiles, and whiskers indicate the range. All observations are represented by a dot. (C) Number of patients with no treatment-emergent mutations. Significantly more patients with no treatment-emergent mutations treated with IFNÎ± achieved CHR (35 of 68 [51%]) compared with patients treated with HU (4 of 18 [22%]) (<italic toggle="yes">P</italic> = .03). (D) Number of patients with treatment-emergent mutations. No difference in the number of patients failing to achieve CHR was observed between patients treated with HU (10 of 13 [77%]) or IFNÎ± (9 of 14 [64%]) (<italic toggle="yes">P</italic> = .68). (E) Number of patients with treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations. (F) Number of patients with treatment-emergent non-<italic toggle="yes">DNMT3A</italic> mutations. Treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations were significantly enriched in patients treated with IFNÎ± failing to achieve CHR (8 of 9 [89%]) compared with treatment-emergent non-<italic toggle="yes">DNMT3A</italic> mutations (1 of 5 [20%]) (<italic toggle="yes">P</italic> = .02).</p>
                  </caption>
                  <graphic xlink:href="advancesADV2021004856f5" position="float"/>
                </fig>
                <p>We divided the patients available for CHR assessment and serial sampling (n = 113) into 2 groups: (1) those in whom no treatment-emergent mutations were detected (HU, n = 18; IFNÎ±, n = 68) (<xref rid="F5" ref-type="fig">Figure 5C</xref>); and (2) those in whom treatment-emergent mutations were detected (HU, n = 13; IFNÎ±, n = 14) (<xref rid="F5" ref-type="fig">Figure 5D</xref>). We further divided the latter group into those in whom <italic toggle="yes">DNMT3A</italic> mutations were detected (HU, n = 2; IFNÎ±, n = 9) (<xref rid="F5" ref-type="fig">Figure 5E</xref>) and those in whom non-<italic toggle="yes">DNMT3A</italic> treatment-emergent mutations were detected (HU, n = 11; IFNÎ±, n = 5) (<xref rid="F5" ref-type="fig">Figure 5F</xref>). Within the group in whom no treatment-emergent mutations were detected, significantly more patients treated with IFNÎ± achieved CHR (35 of 68 [51%]) compared with patients treated with HU (4 of 18 [22%]) (<italic toggle="yes">P</italic> = .034). Of 27 patients with treatment-emergent mutations at 24 months and available for response assessment, 19 (70%) failed to achieve CHR (HU, 10 of 13 [77%]; IFNÎ±, 9 of 14 [64%]) (<italic toggle="yes">P</italic> = .68). We found that treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations were significantly enriched among patients treated with IFNÎ± failing to achieve CHR (8 of 9 [89%]) compared with treatment-emergent non-<italic toggle="yes">DNMT3A</italic> mutations (1 of 5 [20%]) (<italic toggle="yes">P</italic> = .02). Among patients randomized to receive HU, the 2 patients with treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations did not obtain CHR compared with CHR in 3 (27%) of 11 patients with treatment-emergent non-<italic toggle="yes">DNMT3A</italic> mutations.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>To determine the impact of molecular genetics on response to front-line cytoreductive therapy in MPN, we performed sequential molecular profiling on samples obtained from patients enrolled in the DALIAH trial, a randomized controlled, phase 3 clinical trial of IFNÎ± vs HU in patients newly diagnosed with MPN.</p>
              <p>To enable detailed molecular profiling, we first developed a custom targeted NGS assay encompassing 120 myeloid malignancyâassociated genes. A significant age-independent association was found between the presence of a mutation in <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A,</italic> or <italic toggle="yes">ASXL1</italic> at baseline and a history of stroke, which remained significant for mutated <italic toggle="yes">TET2</italic> alone. We also found an association between the presence of a <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A,</italic> or <italic toggle="yes">ASXL1</italic> mutation and a history of major thrombosis. However, this association did not retain significance when adjusted for age. Previous studies have found an age-independent association between the presence of one or more mutations in <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A,</italic> or <italic toggle="yes">ASXL1</italic> and thrombotic events in PV, which was retained for the presence of a <italic toggle="yes">TET2</italic> mutation alone.<sup><xref rid="B43" ref-type="bibr">43</xref></sup> However, an association between <italic toggle="yes">TET2</italic>, <italic toggle="yes">DNMT3A,</italic> or <italic toggle="yes">ASXL1</italic> mutations and thrombosis in PV was not found in earlier studies.<sup><xref rid="B44" ref-type="bibr">44,45</xref></sup> A novel feature of the NGS assay was the ability to determine the presence of <italic toggle="yes">JAK2</italic>-UPD on 9p, allowing us to distinguish patients who were heterozygous for the <italic toggle="yes">JAK2</italic> mutation from those who were homozygous. This is particularly informative in patients with a <italic toggle="yes">JAK2</italic> VAF &lt;50%. We incorporated <italic toggle="yes">JAK2</italic>-UPD into our analysis of the molecular response, and by combining sequential mutational and <italic toggle="yes">JAK2</italic>-UPD analyses, we were able to uncover distinct treatment responses in independent clones/subclones in individual patients (discussed later).</p>
              <p>In terms of treatment response, we first focused our attention on the 2 most common MPN phenotypic driver mutations, <italic toggle="yes">JAK2</italic> and <italic toggle="yes">CALR</italic>. We found that more patients treated with IFNÎ± had a decrease in the mutant <italic toggle="yes">JAK2</italic> VAF than patients treated with HU. Furthermore, the median mutant <italic toggle="yes">JAK2</italic> VAF reduction was significantly greater among patients treated with IFNÎ± than with HU. In contrast, there was no difference in the magnitude of decrease in mutant <italic toggle="yes">CALR</italic> VAF in patients treated with HU than with IFNÎ±, and the median reduction in mutant <italic toggle="yes">CALR</italic> VAF was &lt;5% for both HU and IFNÎ±. We found that patients with <italic toggle="yes">JAK2</italic>-UPD treated with IFNÎ± had a greater decrease in <italic toggle="yes">JAK2</italic> VAF than <italic toggle="yes">JAK2-</italic>mutated patients without <italic toggle="yes">JAK2</italic>-UPD (not seen with HU). This finding is consistent with a small prospective study of MPN (n = 33 patients) by Mosca et al,<sup><xref rid="B46" ref-type="bibr">46</xref></sup> who reported (in abstract form) that hematopoietic stem cells homozygous for mutated <italic toggle="yes">JAK2V167F</italic> were more effectively targeted by IFNÎ± than heterozygous cells.</p>
              <p>We next evaluated the association between CHR at 24 months and molecular response. CHR rates were similar at 24 months between HU and IFNÎ±, which is in accordance with data (presented in abstract form) from the randomized Myeloproliferative DisordersâResearch Consortium (MPD-RC) 112 study of high-risk ET or PV comparing HU with IFNÎ±-2a.<sup><xref rid="B47" ref-type="bibr">47</xref></sup> Interestingly, we found that CHR at 24 months was associated with a significant VAF reduction in <italic toggle="yes">JAK2</italic>-mutated patients but not in <italic toggle="yes">CALR</italic>-mutated patients treated with IFNÎ±. Although reductions in mutant <italic toggle="yes">CALR</italic> VAF in response to IFNÎ± treatment have been reported in MPN,<sup><xref rid="B48" ref-type="bibr">48,49</xref></sup> previous smaller studies, including a recent retrospective study (n = 38 patients) reported by Czech et al,<sup><xref rid="B50" ref-type="bibr">50</xref></sup> have suggested that <italic toggle="yes">CALR</italic>-mutant MPN cells are less sensitive to IFNÎ± than <italic toggle="yes">JAK2</italic>-mutated cells.<sup><xref rid="B51" ref-type="bibr">51</xref></sup> Strengths of our findings on this point include that patients were treated in a large prospective randomized trial (n = 202 patients) and that <italic toggle="yes">JAK2</italic> and <italic toggle="yes">CALR</italic> VAF were assessed simultaneously using the same NGS platform. Limitations include the fact that almost one-third of the <italic toggle="yes">CALR</italic> mutant group were patients with PMF (31%), in addition to patients with ET (55%) and Pre-MF (14%), whereas the <italic toggle="yes">JAK2</italic> mutant group was composed primarily of patients with PV (59%) and ET (24%), in addition to patients with Pre-MF (7%) and PMF (10%).</p>
              <p>We next turned our attention to treatment-emergent mutations. By serial sampling at 24 months, 38 treatment-emergent mutations were found in 32 patients. Notably, approximately one-half the time a treatment-emergent mutation was detected on serial sampling, the <italic toggle="yes">JAK2</italic> VAF was found to have declined by &gt;50%, suggesting that the treatment-emergent mutation had arisen independently or was subclonal to the <italic toggle="yes">JAK2</italic> mutant clone. This finding highlights the importance of not restricting molecular analysis in clinical trials to MPN phenotypic driver genes only.</p>
              <p>The gene in which we most commonly identified treatment-emergent mutations was <italic toggle="yes">DNMT3A</italic> (39%), and we found that treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations were significantly more prevalent in patients treated with IFNÎ± failing to achieve CHR. <italic toggle="yes">DNMT3A</italic> mutations have been reported to both precede and follow <italic toggle="yes">JAK2V617F</italic> acquisition, in addition to arising in independent clones in MPN.<sup><xref rid="B52" ref-type="bibr">52,53</xref></sup> As such, these <italic toggle="yes">DNMT3A</italic> mutations could reflect either treatment-resistant subclones or genetically unrelated clones that develop in parallel to the phenotypic driver clone. The methodology we used in this study did not allow us to distinguish whether preexisting <italic toggle="yes">DNMT3A</italic>-mutated clones expanded during treatment with IFNÎ± or <italic toggle="yes">de novo DNMT3A</italic> mutations were induced by IFNÎ±. However, we believe it is highly likely that treatment-emergent <italic toggle="yes">DNMT3A</italic> mutations were preexisting at baseline and selected for with IFNÎ± therapy. In agreement with this model, studies using ultrasensitive error-corrected sequencing have found that most adults aged &gt;50 years have evidence of clonal hematopoiesis, most commonly involving mutations in <italic toggle="yes">DNMT3A</italic>.<sup><xref rid="B54" ref-type="bibr">54</xref></sup> In accordance with our finding, QuintÃ¡s-Cardama et al<sup><xref rid="B33" ref-type="bibr">33</xref></sup> found that the acquisition of a <italic toggle="yes">DNMT3A</italic> mutation was associated with failure to achieve complete molecular remission in patients with PV and ET treated with IFNÎ± (n = 83). More recently, Stetka et al<sup><xref rid="B55" ref-type="bibr">55</xref></sup> reported (in abstract form) that genetic loss of <italic toggle="yes">Dnmt3a</italic> confers resistance to treatment with IFN in a <italic toggle="yes">JAK2V617F</italic>-driven MPN mouse model. Clues to the mechanism by which <italic toggle="yes">Dnmt3a</italic> loss could render hematopoietic stem and progenitor cells resistant to IFNÎ± are suggested by Jacquelin et al, who found that <italic toggle="yes">Dnmt3a</italic> loss induced aberrant self-renewal of <italic toggle="yes">Jak2</italic>-mutant hematopoietic stem and progenitor cells and augmented pro-inflammatory signaling due to increased chromatin accessibility.<sup><xref rid="B56" ref-type="bibr">56,57</xref></sup> It is important to note that the majority of <italic toggle="yes">DNMT3A</italic> mutations found in MPN (and in this study) are heterozygous missense mutations that do not result in complete loss of <italic toggle="yes">DNMT3A</italic> function. Mutations in <italic toggle="yes">PPM1D</italic> or <italic toggle="yes">TP53</italic> were found more frequently in patients treated with HU, a finding consistent with several earlier reports linking mutations in these genes to chemotherapy exposure in other contexts.<sup><xref rid="B58" ref-type="bibr">58-61</xref></sup> However, it is important to note that low allele burden <italic toggle="yes">TP53</italic> mutations have been associated with older age in chronic-phase MPN, and randomization to HU was restricted to patients aged &gt;60 years in our study.<sup><xref rid="B62" ref-type="bibr">62</xref></sup></p>
              <p>In the current study, molecular response was assessed at 24 months. In previous studies, the <italic toggle="yes">JAK2</italic> molecular response has been shown to increase gradually with time upon treatment with IFNÎ±,<sup><xref rid="B28" ref-type="bibr">28-36</xref></sup> whereas the molecular response is often transient in patients treated with HU.<sup><xref rid="B25" ref-type="bibr">25-27</xref>,<xref rid="B30" ref-type="bibr">30</xref></sup> In the recently reported randomized CONTINUATION-PV trial of 171 patients with PV allocated to receive ropeginterferon Î±-2b (ropeg) or best available therapy (mainly HU), significantly higher <italic toggle="yes">JAK2</italic> molecular responses were observed among patients treated with ropeg after 24 and 36 months of treatment.<sup><xref rid="B30" ref-type="bibr">30</xref></sup> Furthermore, the higher <italic toggle="yes">JAK2</italic> molecular response rate in the ropeg arm was even more striking after 48 months and was sustained at 60 months.<sup><xref rid="B63" ref-type="bibr">63</xref></sup> This is consistent with the reported durable <italic toggle="yes">JAK2</italic> molecular responses beyond 5 years in patients with ET and PV treated with IFNÎ±-2a.<sup><xref rid="B32" ref-type="bibr">32</xref></sup> Notably, ropeg, which is dosed every 2 weeks, seemed to be well tolerated in the CONTINUATION-PV trial,<sup><xref rid="B64" ref-type="bibr">64</xref></sup> in contrast to our study, in which 34% of the IFNÎ±âtreated patients discontinued study medication for toxicity within 24 months, despite a low-dose regimen.</p>
              <p>Although NGS technologies are increasingly used in clinical practice to provide prognostic information and guide treatment decisions in MPN, sequential genomic profiling is not usually performed outside of clinical trials. In terms of counseling patients on the possible molecular consequences of cytoreductive therapy, our findings can be summarized as follows: (1) coexisting mutations are present at diagnosis in â¼50% of patients with ET and PV; (2) concomitant mutations may be present in the same cell or a different cell than the MPN disease-initiating mutation (ie, <italic toggle="yes">JAK2</italic>, <italic toggle="yes">CALR</italic>, <italic toggle="yes">MPL</italic>); and (3) not all mutations respond in the same way to IFNÎ± or HU treatment. It is important to acknowledge that we currently have an incomplete understanding of the clinical significance of concomitant mutations in ET and PV, particularly with respect to treatment. Therefore, additional studies with long follow-up are required to understand the clinical significance of an IFNÎ±âinduced reduction in <italic toggle="yes">JAK2V617F</italic> allele burden and mutations, such as <italic toggle="yes">DNMT3A</italic>, expanding during IFNÎ± treatment.</p>
              <p>Because the primary goal of cytoreductive therapy in MPN is to reduce the risk of thrombotic and vascular events, we are not suggesting any immediate change in clinical practice based on our results. However, we suggest several next steps to further advance the understanding of the differential effects of cytoreductive therapy on clonal MPN cells: (1) aggregate currently available molecular genetic data on patients treated with IFNÎ± to increase statistical power and further validate key findings; (2) perform sequential NGS analysis in prospective clinical trials of cytoreductive therapy in PV and ET, and correlate early molecular findings with long-term clinical outcomes (ie, identify molecular genetic biomarkers that predict clinical outcome); and (3) develop low-cost methodologies to enable sequential molecular genetic analysis as a routine component of MPN clinical care.</p>
              <p>Finally, newly emerging data have shown that acquisition of the <italic toggle="yes">JAK2V617F</italic> mutation may occur decades before the development of MPN,<sup><xref rid="B65" ref-type="bibr">65,66</xref></sup> consistent with a long preclinical phase termed <italic toggle="yes">JAK2</italic>-mutant clonal hematopoiesis (CH). Although not all patients with <italic toggle="yes">JAK2</italic>-mutant CH develop MPN, it is a clinically relevant entity associated with an increased risk of cardiovascular disease<sup><xref rid="B67" ref-type="bibr">67</xref></sup> and venous thrombosis.<sup><xref rid="B68" ref-type="bibr">68,69</xref></sup> Due to the ability of IFNÎ± to reduce the <italic toggle="yes">JAK2</italic>-mutated clone,<sup><xref rid="B70" ref-type="bibr">70</xref></sup> early identification and upfront treatment of individuals with <italic toggle="yes">JAK2</italic>-mutant CH raise the possibility that IFNÎ± could have the potential to prevent the development of MPN and/or decrease <italic toggle="yes">JAK2</italic>-mutant CH-associated morbidity and mortality. The development of specialized CH clinics to identify such individuals and offer them clinical trials (eg, with IFNÎ±) is a recent development in this regard.<sup><xref rid="B71" ref-type="bibr">71</xref></sup></p>
              <p>In conclusion, we performed comprehensive molecular profiling of patients with newly diagnosed MPN treated with front-line cytoreductive therapy (IFNÎ± vs HU) and identified treatment- and mutation-specific patterns of response that have clinical implications.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <p>The full-text version of this article contains a data supplement.</p>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <media xlink:href="advancesADV2021004856-suppl1.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors thank all the participating patients and their families, all investigators, research coordinators, and site staff in Denmark.</p>
              <p>The sponsors of this study are nonprofit organizations that support science in general. They had no role in gathering, analyzing, or interpreting the data.</p>
              <p>This research was supported by grants from OUH Frie Forskningsmidler, OUH-Region Sjaelland Faelles Forskningspulje, Fonden til LÃ¦gevidenskabens Fremme, Ellen og Aage Fausboells Helsefond af 1975, Swedish Orphan, Region Sjaellands Sundhedsvidenskabelige Forskningsfond (Ordinaer), Region SjÃ¦llands Sundhedsvidenskabelige Forskningsfond (RSSF) 2018, Gangstefonden, and the National Institutes of Health, National Cancer Institute (K08CA204734, R.C.L.). The NGS studies were funded by an Interferon Initiative grant (A.M.) from the MPN Research Foundation. A.M. acknowledges funding from the National Institutes of Health, National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL131835). A.M. is a Scholar of The Leukemia &amp; Lymphoma Society.</p>
            </ack>
            <sec>
              <title>Authorship</title>
              <p>Contribution: A.M., H.C.H., and R.C.L designed the study, analyzed and interpreted data, edited the manuscript, and oversaw the study; R.C.L. designed and performed genomic analyses and created figures; T.A. Knudsen collected clinical data, analyzed and interpreted data, created figures, and wrote the first version of the manuscript; L.F.O. collected clinical data; D.L.H. constructed the clinical database; C.E., D.L.H., L.K., T.S.L., and V.S. analyzed and interpreted data and edited the manuscript; W.D. processed samples and analyzed data; C.L. analyzed data; D.S.N., L.W., K.S., and T.A. Knudsen performed statistical analysis; D.E.F., D.L.H., J. Starklint, J. Stentoft, K.d.S., M.F., M.B., M.T., M.T.S., O.W.B., T.A. Kruse, T.M.-A., T.K.K., T.S.L., and U.M.O. performed research; C.J.G. analyzed NGS data; A.N., A.R.T., and B.W. oversaw the generation of NGS data; and all authors reviewed the manuscript.</p>
              <p>Conflict-of-interest disclosure: D.L.H. received research funding from Alexion. D.S.N. received research funding from Celgene and Pharmacyclics; and has equity ownership in Madrigal Pharmaceuticals. H.C.H. has received research funding from Novartis; and is on the data monitoring board for AOP Orphan. R.C.L. has received research funding from Jazz Pharmaceuticals and MedImmune; and consultancy for Takeda Pharmaceuticals and Bluebird Bio. A.M. reports research funding and consulting for Janssen; research funding from Actuate Therapeutics; advisory board membership for Constellation; steering committee membership for PharmaEssentia; and consulting for Relay Therapeutics.</p>
              <p>Correspondence: Ann Mullally, Harvard Institutes of Medicine Building, Room 738, 77 Ave Louis Pasteur, Boston, MA 02115; e-mail: ann_mullally@dfci.harvard.edu.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dameshek</surname><given-names>W</given-names></string-name></person-group>. <article-title>Some speculations on the myeloproliferative syndromes</article-title>. <source>Blood.</source><year>1951</year>;<volume>6</volume>(<issue>4</issue>):<fpage>372</fpage>-<lpage>375</lpage>.<pub-id pub-id-type="pmid">14820991</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arber</surname><given-names>DA</given-names></string-name>, <string-name><surname>Orazi</surname><given-names>A</given-names></string-name>, <string-name><surname>Hasserjian</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</article-title>. <source>Blood.</source><year>2016</year>;<volume>127</volume>(<issue>20</issue>):<fpage>2391</fpage>-<lpage>2405</lpage>.<pub-id pub-id-type="pmid">27069254</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hultcrantz</surname><given-names>M</given-names></string-name>, <string-name><surname>Kristinsson</surname><given-names>SY</given-names></string-name>, <string-name><surname>Andersson</surname><given-names>TML</given-names></string-name>, <etal/></person-group>. <article-title>Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study</article-title>. <source>J Clin Oncol.</source><year>2012</year>;<volume>30</volume>(<issue>24</issue>):<fpage>2995</fpage>-<lpage>3001</lpage>.<pub-id pub-id-type="pmid">22802311</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaifie</surname><given-names>A</given-names></string-name>, <string-name><surname>Kirschner</surname><given-names>M</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>D</given-names></string-name>, <etal/>; <collab>Study Alliance Leukemia (SAL)</collab></person-group>. <article-title>Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry</article-title>. <source>J Hematol Oncol.</source><year>2016</year>;<volume>9</volume>(<issue>1</issue>):<fpage>18</fpage>.<pub-id pub-id-type="pmid">26944254</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>HulegÃ¥rdh</surname><given-names>E</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>C</given-names></string-name>, <string-name><surname>Lazarevic</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry</article-title>. <source>Am J Hematol.</source><year>2015</year>;<volume>90</volume>(<issue>3</issue>):<fpage>208</fpage>-<lpage>214</lpage>.<pub-id pub-id-type="pmid">25421221</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mead</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Mullally</surname><given-names>A</given-names></string-name></person-group>. <article-title>Myeloproliferative neoplasm stem cells</article-title>. <source>Blood.</source><year>2017</year>;<volume>129</volume>(<issue>12</issue>):<fpage>1607</fpage>-<lpage>1616</lpage>.<pub-id pub-id-type="pmid">28159736</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marneth</surname><given-names>AE</given-names></string-name>, <string-name><surname>Mullally</surname><given-names>A</given-names></string-name></person-group>. <article-title>The molecular genetics of myeloproliferative neoplasms</article-title>. <source>Cold Spring Harb Perspect Med.</source><year>2020</year>;<volume>10</volume>(<issue>2</issue>):<fpage>a034876</fpage>.<pub-id pub-id-type="pmid">31548225</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baxter</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Scott</surname><given-names>LM</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>PJ</given-names></string-name>, <etal/>; <collab>Cancer Genome Project</collab></person-group>. <article-title>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</article-title>. <source>Lancet.</source><year>2005</year>;<volume>365</volume>(<issue>9464</issue>):<fpage>1054</fpage>-<lpage>1061</lpage>.<pub-id pub-id-type="pmid">15781101</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>James</surname><given-names>C</given-names></string-name>, <string-name><surname>Ugo</surname><given-names>V</given-names></string-name>, <string-name><surname>Le CouÃ©dic</surname><given-names>JP</given-names></string-name>, <etal/></person-group>. <article-title>A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</article-title>. <source>Nature.</source><year>2005</year>;<volume>434</volume>(<issue>7037</issue>):<fpage>1144</fpage>-<lpage>1148</lpage>.<pub-id pub-id-type="pmid">15793561</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kralovics</surname><given-names>R</given-names></string-name>, <string-name><surname>Passamonti</surname><given-names>F</given-names></string-name>, <string-name><surname>Buser</surname><given-names>AS</given-names></string-name>, <etal/></person-group>. <article-title>A gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title>. <source>N Engl J Med.</source><year>2005</year>;<volume>352</volume>(<issue>17</issue>):<fpage>1779</fpage>-<lpage>1790</lpage>.<pub-id pub-id-type="pmid">15858187</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Levine</surname><given-names>RL</given-names></string-name>, <string-name><surname>Wadleigh</surname><given-names>M</given-names></string-name>, <string-name><surname>Cools</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</article-title>. <source>Cancer Cell.</source><year>2005</year>;<volume>7</volume>(<issue>4</issue>):<fpage>387</fpage>-<lpage>397</lpage>.<pub-id pub-id-type="pmid">15837627</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>LM</given-names></string-name>, <string-name><surname>Tong</surname><given-names>W</given-names></string-name>, <string-name><surname>Levine</surname><given-names>RL</given-names></string-name>, <etal/></person-group>. <article-title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis</article-title>. <source>N Engl J Med.</source><year>2007</year>;<volume>356</volume>(<issue>5</issue>):<fpage>459</fpage>-<lpage>468</lpage>.<pub-id pub-id-type="pmid">17267906</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Milosevic Feenstra</surname><given-names>JD</given-names></string-name>, <string-name><surname>Nivarthi</surname><given-names>H</given-names></string-name>, <string-name><surname>Gisslinger</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms</article-title>. <source>Blood.</source><year>2016</year>;<volume>127</volume>(<issue>3</issue>):<fpage>325</fpage>-<lpage>332</lpage>.<pub-id pub-id-type="pmid">26423830</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angona</surname><given-names>A</given-names></string-name>, <string-name><surname>FernÃ¡ndez-RodrÃ­guez</surname><given-names>C</given-names></string-name>, <string-name><surname>Alvarez-LarrÃ¡n</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing</article-title>. <source>Blood Cancer J.</source><year>2016</year>;<volume>6</volume>(<issue>8</issue>):<fpage>e463</fpage>.<pub-id pub-id-type="pmid">27564461</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skov</surname><given-names>V</given-names></string-name></person-group>. <article-title>Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses</article-title>. <source>Cancers (Basel).</source><year>2020</year>;<volume>12</volume>(<issue>8</issue>):<fpage>1</fpage>-<lpage>38</lpage>.</mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lundberg</surname><given-names>P</given-names></string-name>, <string-name><surname>Karow</surname><given-names>A</given-names></string-name>, <string-name><surname>Nienhold</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms</article-title>. <source>Blood.</source><year>2014</year>; <volume>123</volume>(<issue>14</issue>):<fpage>2220</fpage>-<lpage>2228</lpage>.<pub-id pub-id-type="pmid">24478400</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grinfeld</surname><given-names>J</given-names></string-name>, <string-name><surname>Nangalia</surname><given-names>J</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>EJ</given-names></string-name>, <etal/></person-group>. <article-title>Classification and personalized prognosis in myeloproliferative neoplasms</article-title>. <source>N Engl J Med.</source><year>2018</year>;<volume>379</volume>(<issue>15</issue>): <fpage>1416</fpage>-<lpage>1430</lpage>.<pub-id pub-id-type="pmid">30304655</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vannucchi</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lasho</surname><given-names>TL</given-names></string-name>, <string-name><surname>Guglielmelli</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Mutations and prognosis in primary myelofibrosis</article-title>. <source>Leukemia.</source><year>2013</year>;<volume>27</volume>(<issue>9</issue>):<fpage>1861</fpage>-<lpage>1869</lpage>.<pub-id pub-id-type="pmid">23619563</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guglielmelli</surname><given-names>P</given-names></string-name>, <string-name><surname>Lasho</surname><given-names>TL</given-names></string-name>, <string-name><surname>Rotunno</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients</article-title>. <source>Leukemia.</source><year>2014</year>;<volume>28</volume>(<issue>9</issue>):<fpage>1804</fpage>-<lpage>1810</lpage>.<pub-id pub-id-type="pmid">24549259</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tefferi</surname><given-names>A</given-names></string-name>, <string-name><surname>Guglielmelli</surname><given-names>P</given-names></string-name>, <string-name><surname>Lasho</surname><given-names>TL</given-names></string-name>, <etal/></person-group>. <article-title>Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera</article-title>. <source>Br J Haematol.</source><year>2020</year>;<volume>189</volume>(<issue>2</issue>):<fpage>291</fpage>-<lpage>302</lpage>.<pub-id pub-id-type="pmid">31945802</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ortmann</surname><given-names>CA</given-names></string-name>, <string-name><surname>Kent</surname><given-names>DG</given-names></string-name>, <string-name><surname>Nangalia</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Effect of mutation order on myeloproliferative neoplasms</article-title>. <source>N Engl J Med.</source><year>2015</year>;<volume>372</volume>(<issue>7</issue>):<fpage>601</fpage>-<lpage>612</lpage>.<pub-id pub-id-type="pmid">25671252</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cortelazzo</surname><given-names>S</given-names></string-name>, <string-name><surname>Finazzi</surname><given-names>G</given-names></string-name>, <string-name><surname>Ruggeri</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis</article-title>. <source>N Engl J Med.</source><year>1995</year>;<volume>332</volume>(<issue>17</issue>):<fpage>1132</fpage>-<lpage>1136</lpage>.<pub-id pub-id-type="pmid">7700286</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fruchtman</surname><given-names>SM</given-names></string-name>, <string-name><surname>Mack</surname><given-names>K</given-names></string-name>, <string-name><surname>Kaplan</surname><given-names>ME</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>P</given-names></string-name>, <string-name><surname>Berk</surname><given-names>PD</given-names></string-name>, <string-name><surname>Wasserman</surname><given-names>LR</given-names></string-name></person-group>. <article-title>From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera</article-title>. <source>Semin Hematol.</source><year>1997</year>;<volume>34</volume>(<issue>1</issue>):<fpage>17</fpage>-<lpage>23</lpage>.<pub-id pub-id-type="pmid">9025158</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrison</surname><given-names>CN</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Buck</surname><given-names>G</given-names></string-name>, <etal/>; <collab>United Kingdom Medical Research Council Primary Thrombocythemia 1 Study</collab></person-group>. <article-title>Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia</article-title>. <source>N Engl J Med.</source><year>2005</year>;<volume>353</volume>(<issue>1</issue>):<fpage>33</fpage>-<lpage>45</lpage>.<pub-id pub-id-type="pmid">16000354</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spanoudakis</surname><given-names>E</given-names></string-name>, <string-name><surname>Bazdiara</surname><given-names>I</given-names></string-name>, <string-name><surname>Kotsianidis</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients</article-title>. <source>Ann Hematol.</source><year>2009</year>;<volume>88</volume>(<issue>7</issue>):<fpage>629</fpage>-<lpage>632</lpage>.<pub-id pub-id-type="pmid">19096846</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsen</surname><given-names>TS</given-names></string-name>, <string-name><surname>Pallisgaard</surname><given-names>N</given-names></string-name>, <string-name><surname>de Stricker</surname><given-names>K</given-names></string-name>, <string-name><surname>MÃ¸ller</surname><given-names>MB</given-names></string-name>, <string-name><surname>Hasselbalch</surname><given-names>HC</given-names></string-name></person-group>. <article-title>Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden</article-title>. <source>Hematology.</source><year>2009</year>;<volume>14</volume>(<issue>1</issue>):<fpage>11</fpage>-<lpage>15</lpage>.<pub-id pub-id-type="pmid">19154659</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Antonioli</surname><given-names>E</given-names></string-name>, <string-name><surname>Carobbio</surname><given-names>A</given-names></string-name>, <string-name><surname>Pieri</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia</article-title>. <source>Haematologica.</source><year>2010</year>;<volume>95</volume>(<issue>8</issue>):<fpage>1435</fpage>-<lpage>1438</lpage>.<pub-id pub-id-type="pmid">20418246</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kiladjian</surname><given-names>J-JJ</given-names></string-name>, <string-name><surname>Cassinat</surname><given-names>B</given-names></string-name>, <string-name><surname>Turlure</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>High molecular response rate of polycythemia vera patients treated with pegylated interferon Î±-2a</article-title>. <source>Blood.</source><year>2006</year>;<volume>108</volume>(<issue>6</issue>):<fpage>2037</fpage>-<lpage>2040</lpage>.<pub-id pub-id-type="pmid">16709929</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>QuintÃ¡s-Cardama</surname><given-names>A</given-names></string-name>, <string-name><surname>Kantarjian</surname><given-names>H</given-names></string-name>, <string-name><surname>Manshouri</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera</article-title>. <source>J Clin Oncol.</source><year>2009</year>;<volume>27</volume>(<issue>32</issue>):<fpage>5418</fpage>-<lpage>5424</lpage>.<pub-id pub-id-type="pmid">19826111</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gisslinger</surname><given-names>H</given-names></string-name>, <string-name><surname>Klade</surname><given-names>C</given-names></string-name>, <string-name><surname>Georgiev</surname><given-names>P</given-names></string-name>, <etal/>; <collab>PROUD-PV Study Group</collab></person-group>. <article-title>Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study</article-title>. <source>Lancet Haematol.</source><year>2020</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e196</fpage>-<lpage>e208</lpage>.<pub-id pub-id-type="pmid">32014125</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kiladjian</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Cassinat</surname><given-names>B</given-names></string-name>, <string-name><surname>Chevret</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera</article-title>. <source>Blood.</source><year>2008</year>;<volume>112</volume>(<issue>8</issue>):<fpage>3065</fpage>-<lpage>3072</lpage>.<pub-id pub-id-type="pmid">18650451</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masarova</surname><given-names>L</given-names></string-name>, <string-name><surname>Patel</surname><given-names>KP</given-names></string-name>, <string-name><surname>Newberry</surname><given-names>KJ</given-names></string-name>, <etal/></person-group>. <article-title>Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial</article-title>. <source>Lancet Haematol.</source><year>2017</year>;<volume>4</volume>(<issue>4</issue>):<fpage>e165</fpage>-<lpage>e175</lpage>.<pub-id pub-id-type="pmid">28291640</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>QuintÃ¡s-Cardama</surname><given-names>A</given-names></string-name>, <string-name><surname>Abdel-Wahab</surname><given-names>O</given-names></string-name>, <string-name><surname>Manshouri</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon Î±-2a</article-title>. <source>Blood.</source><year>2013</year>;<volume>122</volume>(<issue>6</issue>):<fpage>893</fpage>-<lpage>901</lpage>.<pub-id pub-id-type="pmid">23782935</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silver</surname><given-names>RT</given-names></string-name></person-group>. <article-title>Recombinant interferon-alpha for treatment of polycythaemia vera</article-title>. <source>Lancet.</source><year>1988</year>;<volume>2</volume>(<issue>8607</issue>):<fpage>403</fpage>.</mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samuelsson</surname><given-names>J</given-names></string-name>, <string-name><surname>Hasselbalch</surname><given-names>H</given-names></string-name>, <string-name><surname>Bruserud</surname><given-names>O</given-names></string-name>, <etal/>; <collab>Nordic Study Group for Myeloproliferative Disorders</collab></person-group>. <article-title>A phase II trial of pegylated interferon Î±-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life</article-title>. <source>Cancer.</source><year>2006</year>; <volume>106</volume>(<issue>11</issue>):<fpage>2397</fpage>-<lpage>2405</lpage>.<pub-id pub-id-type="pmid">16639737</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stauffer Larsen</surname><given-names>T</given-names></string-name>, <string-name><surname>Iversen</surname><given-names>KF</given-names></string-name>, <string-name><surname>Hansen</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha</article-title>. <source>Leuk Res.</source><year>2013</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1041</fpage>-<lpage>1045</lpage>.<pub-id pub-id-type="pmid">23827351</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Utke Rank</surname><given-names>C</given-names></string-name>, <string-name><surname>Weis Bjerrum</surname><given-names>O</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>TS</given-names></string-name>, <etal/></person-group>. <article-title>Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera</article-title>. <source>Leuk Lymphoma.</source><year>2016</year>; <volume>57</volume>(<issue>2</issue>):<fpage>348</fpage>-<lpage>354</lpage>.<pub-id pub-id-type="pmid">25956046</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsen</surname><given-names>TS</given-names></string-name>, <string-name><surname>Bjerrum</surname><given-names>OW</given-names></string-name>, <string-name><surname>Pallisgaard</surname><given-names>N</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>MT</given-names></string-name>, <string-name><surname>MÃ¸ller</surname><given-names>MB</given-names></string-name>, <string-name><surname>Hasselbalch</surname><given-names>HC</given-names></string-name></person-group>. <article-title>Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera</article-title>. <source>Ann Hematol.</source><year>2008</year>;<volume>87</volume>(<issue>10</issue>):<fpage>847</fpage>-<lpage>850</lpage>.<pub-id pub-id-type="pmid">18481066</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsen</surname><given-names>TS</given-names></string-name>, <string-name><surname>MÃ¸ller</surname><given-names>MB</given-names></string-name>, <string-name><surname>De Stricker</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission</article-title>. <source>Hematology.</source><year>2009</year>;<volume>14</volume>(<issue>6</issue>):<fpage>331</fpage>-<lpage>334</lpage>.<pub-id pub-id-type="pmid">19941739</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Swerdlow</surname><given-names>S</given-names></string-name>, <string-name><surname>Campo</surname><given-names>E</given-names></string-name>, <string-name><surname>Harris</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <source>World Classification of Tumors of Haematopoietic and Lymphoid Tissues.</source><publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC</publisher-name>; <year>2008</year></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barosi</surname><given-names>G</given-names></string-name>, <string-name><surname>Mesa</surname><given-names>R</given-names></string-name>, <string-name><surname>Finazzi</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project</article-title>. <source>Blood.</source><year>2013</year>;<volume>121</volume>(<issue>23</issue>):<fpage>4778</fpage>-<lpage>4781</lpage>.<pub-id pub-id-type="pmid">23591792</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barosi</surname><given-names>G</given-names></string-name>, <string-name><surname>Bordessoule</surname><given-names>D</given-names></string-name>, <string-name><surname>Briere</surname><given-names>J</given-names></string-name>, <etal/>; <collab>European Myelofibrosis Network</collab></person-group>. <article-title>Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)</article-title>. <source>Blood.</source><year>2005</year>;<volume>106</volume>(<issue>8</issue>):<fpage>2849</fpage>-<lpage>2853</lpage>.<pub-id pub-id-type="pmid">15994287</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Segura-DÃ­az</surname><given-names>A</given-names></string-name>, <string-name><surname>Stuckey</surname><given-names>R</given-names></string-name>, <string-name><surname>Florido</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Thrombotic risk detection in patients with polycythemia vera: the predictive role of DNMT3A/TET2/ASXL1 mutations</article-title>. <source>Cancers (Basel).</source><year>2020</year>;<volume>12</volume>(<issue>4</issue>):<fpage>1</fpage>-<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tefferi</surname><given-names>A</given-names></string-name>, <string-name><surname>Lasho</surname><given-names>TL</given-names></string-name>, <string-name><surname>Guglielmelli</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Targeted deep sequencing in polycythemia vera and essential thrombocythemia</article-title>. <source>Blood Adv.</source><year>2016</year>;<volume>1</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">29296692</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cerquozzi</surname><given-names>S</given-names></string-name>, <string-name><surname>Barraco</surname><given-names>D</given-names></string-name>, <string-name><surname>Lasho</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients</article-title>. <source>Blood Cancer J.</source><year>2017</year>;<volume>7</volume>(<issue>12</issue>):<fpage>662</fpage>.<pub-id pub-id-type="pmid">29282357</pub-id></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mosca</surname><given-names>M</given-names></string-name>, <string-name><surname>Lamrani</surname><given-names>L</given-names></string-name>, <string-name><surname>Marzac</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Differential impact of interferon alpha on JAK2V617F and CALR mutated hematopoietic stem and progenitor cells in classical MPN</article-title>. <source>Blood.</source><year>2018</year>;<volume>132</volume>(<issue>suppl 1</issue>):<fpage>4333</fpage>.</mixed-citation>
              </ref>
              <ref id="B47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mascarenhas</surname><given-names>J</given-names></string-name>, <string-name><surname>Kosiorek</surname><given-names>HE</given-names></string-name>, <string-name><surname>Prchal</surname><given-names>JT</given-names></string-name>, <etal/></person-group>. <article-title>Results of the Myeloproliferative NeoplasmsâResearch Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia</article-title>. <source>Blood.</source><year>2018</year>;<volume>132</volume>(<issue>suppl 1</issue>):<fpage>577</fpage>.<pub-id pub-id-type="pmid">29954751</pub-id></mixed-citation>
              </ref>
              <ref id="B48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>KjÃ¦r</surname><given-names>L</given-names></string-name>, <string-name><surname>Cordua</surname><given-names>S</given-names></string-name>, <string-name><surname>HolmstrÃ¶m</surname><given-names>MO</given-names></string-name>, <etal/></person-group>. <article-title>Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment</article-title>. <source>PLoS One.</source><year>2016</year>;<volume>11</volume>(<issue>10</issue>):<fpage>e0165336</fpage>.<pub-id pub-id-type="pmid">27764253</pub-id></mixed-citation>
              </ref>
              <ref id="B49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verger</surname><given-names>E</given-names></string-name>, <string-name><surname>Cassinat</surname><given-names>B</given-names></string-name>, <string-name><surname>Chauveau</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Clinical and molecular response to interferon-Î± therapy in essential thrombocythemia patients with CALR mutations</article-title>. <source>Blood.</source><year>2015</year>;<volume>126</volume>(<issue>24</issue>):<fpage>2585</fpage>-<lpage>2591</lpage>.<pub-id pub-id-type="pmid">26486786</pub-id></mixed-citation>
              </ref>
              <ref id="B50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Czech</surname><given-names>J</given-names></string-name>, <string-name><surname>Cordua</surname><given-names>S</given-names></string-name>, <string-name><surname>Weinbergerova</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>JAK2V617F but not CALR mutations confer increased molecular responses to interferon-Î± via JAK1/STAT1 activation</article-title>. <source>Leukemia.</source><year>2019</year>;<volume>33</volume>(<issue>4</issue>):<fpage>995</fpage>-<lpage>1010</lpage>.<pub-id pub-id-type="pmid">30470838</pub-id></mixed-citation>
              </ref>
              <ref id="B51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jia</surname><given-names>R</given-names></string-name>, <string-name><surname>Kralovics</surname><given-names>R</given-names></string-name></person-group>. <article-title>Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions</article-title>. <source>Int J Hematol.</source><year>2020</year>;<volume>111</volume>(<issue>2</issue>):<fpage>182</fpage>-<lpage>191</lpage>.<pub-id pub-id-type="pmid">31741139</pub-id></mixed-citation>
              </ref>
              <ref id="B52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nangalia</surname><given-names>J</given-names></string-name>, <string-name><surname>Nice</surname><given-names>FL</given-names></string-name>, <string-name><surname>Wedge</surname><given-names>DC</given-names></string-name>, <etal/></person-group>. <article-title>DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype</article-title>. <source>Haematologica.</source><year>2015</year>;<volume>100</volume>(<issue>11</issue>):<fpage>e438</fpage>-<lpage>e442</lpage>.<pub-id pub-id-type="pmid">26250577</pub-id></mixed-citation>
              </ref>
              <ref id="B53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rao</surname><given-names>N</given-names></string-name>, <string-name><surname>Butcher</surname><given-names>CM</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>ID</given-names></string-name>, <etal/></person-group>. <article-title>Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient</article-title>. <source>Br J Haematol.</source><year>2012</year>;<volume>156</volume>(<issue>2</issue>):<fpage>268</fpage>-<lpage>270</lpage>.<pub-id pub-id-type="pmid">21859430</pub-id></mixed-citation>
              </ref>
              <ref id="B54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Young</surname><given-names>AL</given-names></string-name>, <string-name><surname>Challen</surname><given-names>GA</given-names></string-name>, <string-name><surname>Birmann</surname><given-names>BM</given-names></string-name>, <string-name><surname>Druley</surname><given-names>TE</given-names></string-name></person-group>. <article-title>Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults</article-title>. <source>Nat Commun.</source><year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>12484</fpage>.<pub-id pub-id-type="pmid">27546487</pub-id></mixed-citation>
              </ref>
              <ref id="B55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stetka</surname><given-names>J</given-names></string-name>, <string-name><surname>Hansen</surname><given-names>N</given-names></string-name>, <string-name><surname>Kubovcakova</surname><given-names>L</given-names></string-name>, <string-name><surname>Hao-shen</surname><given-names>H</given-names></string-name>, <string-name><surname>Dirnhofer</surname><given-names>S</given-names></string-name>, <string-name><surname>Skoda</surname><given-names>RC</given-names></string-name></person-group>. <article-title>Loss of Dnmt3a confers resistance to pegifn Î± in JAK2-V617F mouse model [abstract]</article-title>. <source>Blood.</source><year>2020</year>;<volume>136</volume>(<issue>Supplement 1</issue>):<fpage>8</fpage>-<lpage>9</lpage>. Abstract 635.<pub-id pub-id-type="pmid">32614959</pub-id></mixed-citation>
              </ref>
              <ref id="B56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jacquelin</surname><given-names>S</given-names></string-name>, <string-name><surname>Straube</surname><given-names>J</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation</article-title>. <source>Blood.</source><year>2018</year>;<volume>132</volume>(<issue>26</issue>):<fpage>2707</fpage>-<lpage>2721</lpage>.<pub-id pub-id-type="pmid">30366920</pub-id></mixed-citation>
              </ref>
              <ref id="B57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skoda</surname><given-names>RC</given-names></string-name></person-group>. <article-title>Accelerating myelofibrosis through loss of <italic toggle="yes">Dnmt3a.</italic></article-title><source>Blood.</source><year>2018</year>;<volume>132</volume>(<issue>26</issue>):<fpage>2703</fpage>-<lpage>2704</lpage>.<pub-id pub-id-type="pmid">30591541</pub-id></mixed-citation>
              </ref>
              <ref id="B58">
                <label>58.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindsley</surname><given-names>RC</given-names></string-name>, <string-name><surname>Saber</surname><given-names>W</given-names></string-name>, <string-name><surname>Mar</surname><given-names>BG</given-names></string-name>, <etal/></person-group>. <article-title>Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation</article-title>. <source>N Engl J Med.</source><year>2017</year>;<volume>376</volume>(<issue>6</issue>):<fpage>536</fpage>-<lpage>547</lpage>.<pub-id pub-id-type="pmid">28177873</pub-id></mixed-citation>
              </ref>
              <ref id="B59">
                <label>59.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibson</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Lindsley</surname><given-names>RC</given-names></string-name>, <string-name><surname>Tchekmedyian</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma</article-title>. <source>J Clin Oncol.</source><year>2017</year>;<volume>35</volume>(<issue>14</issue>):<fpage>1598</fpage>-<lpage>1605</lpage>.<pub-id pub-id-type="pmid">28068180</pub-id></mixed-citation>
              </ref>
              <ref id="B60">
                <label>60.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahn</surname><given-names>JD</given-names></string-name>, <string-name><surname>Miller</surname><given-names>PG</given-names></string-name>, <string-name><surname>Silver</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title><italic toggle="yes">PPM1D</italic>-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells</article-title>. <source>Blood.</source><year>2018</year>;<volume>132</volume>(<issue>11</issue>):<fpage>1095</fpage>-<lpage>1105</lpage>.<pub-id pub-id-type="pmid">29954749</pub-id></mixed-citation>
              </ref>
              <ref id="B61">
                <label>61.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsu</surname><given-names>JI</given-names></string-name>, <string-name><surname>Dayaram</surname><given-names>T</given-names></string-name>, <string-name><surname>Tovy</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy</article-title>. <source>Cell Stem Cell.</source><year>2018</year>;<volume>23</volume>(<issue>5</issue>):<fpage>700</fpage>-<lpage>713.e6</lpage>.<pub-id pub-id-type="pmid">30388424</pub-id></mixed-citation>
              </ref>
              <ref id="B62">
                <label>62.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kubesova</surname><given-names>B</given-names></string-name>, <string-name><surname>Pavlova</surname><given-names>S</given-names></string-name>, <string-name><surname>Malcikova</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status</article-title>. <source>Leukemia.</source><year>2018</year>;<volume>32</volume>(<issue>2</issue>):<fpage>450</fpage>-<lpage>461</lpage>.<pub-id pub-id-type="pmid">28744014</pub-id></mixed-citation>
              </ref>
              <ref id="B63">
                <label>63.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gisslinger</surname><given-names>H</given-names></string-name>, <string-name><surname>Klade</surname><given-names>C</given-names></string-name>, <string-name><surname>Georgiev</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension [abstract]</article-title>. <source>Blood.</source><year>2020</year>;<volume>136</volume>(<issue>supplement 1</issue>):<fpage>33</fpage>. Abstract 481.</mixed-citation>
              </ref>
              <ref id="B64">
                <label>64.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gisslinger</surname><given-names>H</given-names></string-name>, <string-name><surname>Klade</surname><given-names>C</given-names></string-name>, <string-name><surname>Georgiev</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Ropeginterferon alfa-2b: efficacy and safety in different age groups</article-title>. <source>HemaSphere.</source><year>2020</year>;<volume>4</volume>(<issue>6</issue>):<fpage>e485</fpage>.<pub-id pub-id-type="pmid">33134869</pub-id></mixed-citation>
              </ref>
              <ref id="B65">
                <label>65.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Egeren</surname><given-names>D</given-names></string-name>, <string-name><surname>Escabi</surname><given-names>J</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms</article-title>. <source>Cell Stem Cell.</source><year>2021</year>;<volume>28</volume>(<issue>3</issue>):<fpage>514</fpage>-<lpage>523.e9</lpage>.<pub-id pub-id-type="pmid">33621486</pub-id></mixed-citation>
              </ref>
              <ref id="B66">
                <label>66.</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Williams</surname><given-names>N</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Moore</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Phylogenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution</article-title>. <source>bioRxiv.</source> Posted online November 9, 2020.</mixed-citation>
              </ref>
              <ref id="B67">
                <label>67.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jaiswal</surname><given-names>S</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>P</given-names></string-name>, <string-name><surname>Silver</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease</article-title>. <source>N Engl J Med.</source><year>2017</year>;<volume>377</volume>(<issue>2</issue>):<fpage>111</fpage>-<lpage>121</lpage>.<pub-id pub-id-type="pmid">28636844</pub-id></mixed-citation>
              </ref>
              <ref id="B68">
                <label>68.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cordua</surname><given-names>S</given-names></string-name>, <string-name><surname>Kjaer</surname><given-names>L</given-names></string-name>, <string-name><surname>Skov</surname><given-names>V</given-names></string-name>, <string-name><surname>Pallisgaard</surname><given-names>N</given-names></string-name>, <string-name><surname>Hasselbalch</surname><given-names>HC</given-names></string-name>, <string-name><surname>Ellervik</surname><given-names>C</given-names></string-name></person-group>. <article-title>Prevalence and phenotypes of <italic toggle="yes">JAK2</italic> V617F and <italic toggle="yes">calreticulin</italic> mutations in a Danish general population</article-title>. <source>Blood.</source><year>2019</year>;<volume>134</volume>(<issue>5</issue>):<fpage>469</fpage>-<lpage>479</lpage>.<pub-id pub-id-type="pmid">31217187</pub-id></mixed-citation>
              </ref>
              <ref id="B69">
                <label>69.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolach</surname><given-names>O</given-names></string-name>, <string-name><surname>Sellar</surname><given-names>RS</given-names></string-name>, <string-name><surname>Martinod</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms</article-title>. <source>Sci Transl Med.</source><year>2018</year>;<volume>10</volume>(<issue>436</issue>):<fpage>eaan8292</fpage>.<pub-id pub-id-type="pmid">29643232</pub-id></mixed-citation>
              </ref>
              <ref id="B70">
                <label>70.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pedersen</surname><given-names>RK</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>M</given-names></string-name>, <string-name><surname>Knudsen</surname><given-names>TA</given-names></string-name>, <etal/></person-group>. <article-title>Data-driven analysis of JAK2 V617F kinetics during interferon- alpha2 treatment of patients with polycythemia vera and related neoplasms</article-title>. <source>Cancer Med.</source><year>2020</year>;<volume>9</volume>(<issue>6</issue>):<fpage>2039</fpage>-<lpage>2051</lpage>.<pub-id pub-id-type="pmid">31991066</pub-id></mixed-citation>
              </ref>
              <ref id="B71">
                <label>71.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steensma</surname><given-names>DP</given-names></string-name>, <string-name><surname>Bolton</surname><given-names>KL</given-names></string-name></person-group>. <article-title>What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics</article-title>. <source>Blood.</source><year>2020</year>;<volume>136</volume>(<issue>14</issue>): <fpage>1623</fpage>-<lpage>1631</lpage>.<pub-id pub-id-type="pmid">32736381</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
